Biogen · 11 hours ago
Associate Director, Pharmacovigilance Scientist
Maximize your interview chances
BiotechnologyHealth Care
Comp. & BenefitsH1B Sponsor Likely
Insider Connection @Biogen
Get 3x more responses when you reach out via email instead of LinkedIn.
Responsibilities
Lead independently and collaboratively all aspects of substantive projects including authoring aggregate safety reports and responses to regulatory agency requests.
Serve as a subject matter expert on relevant safety requirements, company policies/procedures related to pharmacovigilance activities, as well as in-depth Aggregate Reports knowledge. Serve as example for behaviors that lead to high quality outputs.
Responsible for the Aggregate Reports Master Schedule and worldwide legislation overview.
Identify process non-compliance, gaps or inefficiencies and lead initiatives for process improvement, implements and maintains processes. Manage corrective actions when non-compliances are identified.
Oversee and mentor PV Scientist staff.
Qualification
Find out how your skills align with this job's requirements. If anything seems off, you can easily click on the tags to select or unselect skills to reflect your actual expertise.
Required
Bachelor’s Degree in biologic or natural science OR Advanced degree (MSc, PhD, MPH, PharmD, etc.)
Minimum 8-10 years Pharmacovigilance experience, including experience in aggregate safety reports writing, responses to health authorities, and safety signal management in both clinical trial setting and post-marketing.
Company
Biogen
Biogen is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
H1B Sponsorship
Biogen has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2023 (75)
2022 (131)
2021 (109)
2020 (112)
Funding
Current Stage
Public CompanyTotal Funding
$1.5BKey Investors
JP Morgan
2023-09-01Post Ipo Debt· $1.5B
1991-09-27IPO
Leadership Team
Recent News
2024-12-17
2024-12-17
2024-12-17
Company data provided by crunchbase